Benign Prostat Hiperplazisi ve Alt Üriner Sistem Semptomları (Luts)
Özet
Referanslar
Roehrborn CG. Benign Prostatic Hyperplasia: An Overview. Reviews in Urology. MedReviews, LLC; 2005;7(Suppl 9): S3–S14.
Cornu JN, Gacci M, Hashim H, et al. EAU Guidelines on Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS). European Association of Urology Guidelines. European Association of Urology; 2025. (Erişim: 21/02/2026).
Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. The Journal of Urology. American Urological Association; 2024;211(1): 11–19. doi:10.1097/JU.0000000000003698
Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urologic Clinics of North America. Elsevier; 2016;43(3): 289–297. doi:10.1016/j.ucl.2016.04.001
McVary KT. BPH: Epidemiology and Comorbidities. The American Journal of Managed Care. 2006;12(Suppl): S122–S128.
Park HJ, Won JEJ, Sorsaburu S, et al. Urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: a systematic review focusing on tadalafil. World Journal of Men’s Health. Korean Society for Sexual Medicine and Andrology; 2013;31(3): 193–207. doi:10.5534/wjmh.2013.31.3.193
Jiwrajka M, Yaxley W, Perera M, et al. Review and update of benign prostatic hyperplasia in general practice. Australian Journal of General Practice. Royal Australian College of General Practitioners; 2018;47(7): 471–476.
Chapple CR, Montorsi F, Tammela TLJ, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. European Urology. European Association of Urology; 2011;59: 342–352. doi:10.1016/j.eururo.2010.10.046
Christidis D, McGrath S, Perera M, et al. Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies. Prostate International. Asian Pacific Prostate Society; 2017;5: 41–46. doi:10.1016/j.prnil.2017.01.007
Yu X, Elliott SP, Wilt TJ, McBean AM. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. The Journal of Urology. 2008;180: 241–245.
Referanslar
Roehrborn CG. Benign Prostatic Hyperplasia: An Overview. Reviews in Urology. MedReviews, LLC; 2005;7(Suppl 9): S3–S14.
Cornu JN, Gacci M, Hashim H, et al. EAU Guidelines on Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS). European Association of Urology Guidelines. European Association of Urology; 2025. (Erişim: 21/02/2026).
Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. The Journal of Urology. American Urological Association; 2024;211(1): 11–19. doi:10.1097/JU.0000000000003698
Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urologic Clinics of North America. Elsevier; 2016;43(3): 289–297. doi:10.1016/j.ucl.2016.04.001
McVary KT. BPH: Epidemiology and Comorbidities. The American Journal of Managed Care. 2006;12(Suppl): S122–S128.
Park HJ, Won JEJ, Sorsaburu S, et al. Urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: a systematic review focusing on tadalafil. World Journal of Men’s Health. Korean Society for Sexual Medicine and Andrology; 2013;31(3): 193–207. doi:10.5534/wjmh.2013.31.3.193
Jiwrajka M, Yaxley W, Perera M, et al. Review and update of benign prostatic hyperplasia in general practice. Australian Journal of General Practice. Royal Australian College of General Practitioners; 2018;47(7): 471–476.
Chapple CR, Montorsi F, Tammela TLJ, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. European Urology. European Association of Urology; 2011;59: 342–352. doi:10.1016/j.eururo.2010.10.046
Christidis D, McGrath S, Perera M, et al. Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies. Prostate International. Asian Pacific Prostate Society; 2017;5: 41–46. doi:10.1016/j.prnil.2017.01.007
Yu X, Elliott SP, Wilt TJ, McBean AM. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. The Journal of Urology. 2008;180: 241–245.
